MétaCan
Menu
← Back to cohort
Record W4388588499 · doi:10.1093/neuonc/noad179.0556

IMMU-24. SALVAGE IMMUNOTHERAPIES FOR REPLICATION REPAIR DEFICIENT (RRD) HIGH-GRADE GLIOMA FAILING ANTI-PD1 MONOTHERAPY: A REPORT FROM THE INTERNATIONAL RRD CONSORTIUM

2023· article· en· W4388588499 on OpenAlexaff
Anirban Das, Nicholas Fernandez, Adrian Levine, Vanessa Bianchi, Lucie Stengs, Melissa Edwards, Liana Nobre, Derek S. Tsang, Birgit Ertl‐Wagner, Daniel A. Morgenstern, Adam Shlien, Cynthia Hawkins, Éric Bouffet, Uri Tabori, Trevor J. Pugh

Bibliographic record

VenueNeuro-Oncology · 2023
Typearticle
Languageen
FieldMedicine
TopicGlioma Diagnosis and Treatment
Canadian institutionsPrincess Margaret Cancer CentreHospital for Sick Children
Fundersnot available
KeywordsIpilimumabMedicineInternal medicineOncologyExpanded accessNivolumabImmune checkpointProgression-free survivalProgressive diseaseSalvage therapyImmunotherapySurgeryChemotherapyCancer

Abstract

fetched live from OpenAlex

Abstract BACKGROUND Initial response to immune checkpoint inhibition (ICI) for DNA replication-repair deficient high-grade glioma (RRD-HGG) is encouraging. However, clinical/biologic implications of immune-directed approaches after failing ICI-monotherapy remain unknown. METHODS We performed an international study of patients managed using central review/treatment recommendations (2015-2021). Salvage after anti-PD1 failure included re-irradiation where feasible, and addition of anti-CTLA4 (ipilimumab), or a MEK-inhibitor (MEKi). Outcomes included radiological response (iRANO), toxicity, second progression-free (PFS2) and overall survival (OS2). Companion biomarkers were performed centrally. RESULTS Twenty among 75 patients treated on anti-PD1 monotherapy are progression-free at a median follow-up of 44.6-months. For 55 patients with relapsed/progressive tumors, continuation of ICI (n=38) resulted in median OS2 of 11.6-months (51% alive) versus 1.2-months when ICI was discontinued (n=17; no survivors, p< 0.001). Addition of ipilimumab (n=24) resulted in response/stable disease in 75% with median OS2 of 12.1-months. High autoimmune toxicities (54%) were observed, particularly in constitutional mismatch-repair deficiency patients. The addition of MEKi led to response in 3/5 patients with prolonged survival. The addition of re-irradiation improved median OS2, especially in tumors with lower mutation burden (p=0.002), and those who received ipilimumab (median OS2=33-months). Several biological insights were gained. Increased CTLA4 expression explained responses to ipilimumab. Re-irradiation responses were attributed to the absence of radio-resistant indel signature (ID8). Early radiological ‘flare’ was observed in 33% on combined immunotherapy and re-radiation. MEKi responses were associated with reinvigoration of peripheral immune response. Finally, delayed, sustained responses were observed in ultra-hypermutant RRD-HGG exhibiting changes in somatic mutational spectra. CONCLUSION These data suggest that the continuous mutagenesis renders hypermutant RRD-HGG susceptible to checkpoint inhibitors beyond initial progression. The combination with re-irradiation and additional immune/targeted agents can maximize survival in these children and young adults. Future research should focus on biology-driven rational immunotherapy combinations that also result in lower toxicity to maximize patient benefit.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.005
Threshold uncertainty score0.025

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.002
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.037
GPT teacher head0.326
Teacher spread0.288 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2023
Admission routes1
Has abstractyes

Explore more

Same venueNeuro-Oncology→Same topicGlioma Diagnosis and Treatment→French-language works237,207→